A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Inclusion Criteria: * Men or women ≥ 18 years of age * Must have a pathologically documented, and definitively diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy * Evaluable OR measurable disease by RECIST 1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 * Life expectancy of \> 3 months, in the opinion of and as documented by the investigator * Subject or subject's legally acceptable representative has provided informed consent Exclusion Criteria: * Subjects with gastric cancer or any malignancy with purely squamous cell histology * Known history of primary central nervous system (CNS) tumors or CNS metastases * Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association \> class II, uncontrolled hypertension \[diastolic \> 90 mmHg; systolic \> 150 mmHg in repeated measurements\]) * History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1 * Active grade 2 or greater peripheral vascular disease or peripheral edema * History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) * Non-healing wound, ulcer (including gastrointestinal) or fracture * Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection * Major surgery within 4 weeks before study day 1 * Absolute neutrophils count (ANC) \< 1.0 x 10\^9/L; or platelet count \< 100 x 10\^9/L; or hemoglobin \< 9 g/dL; or PTT / aPTT \> 1.5 x institutional upper limit of normal (ULN) ); or INR \> 1.5 * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN (\> 5.0 x ULN if liver metastases present) * Alkaline phosphatase \> 2.5 x ULN (\> 5.0 x ULN if attributable to liver or bone metastasis) * Total bilirubin \> 1.5 x ULN * Other investigational procedures during the study * Previous anti-cancer therapy or investigational agent within 4 weeks prior to study day 1 * Anticoagulation therapy within 4 weeks of study day 1 and while on study (except low dose warfarin (≤ 2 mg/kg) for prophylaxis against central venous catheter thrombosis) * Men and women of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386. Highly effective methods of birth control include sexual abstinence (men, women); vasectomy or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women). * Women who are lactating/breastfeeding. * Women with a positive pregnancy test.